Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection
- PMID: 3304600
- PMCID: PMC1492778
Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection
Abstract
The ecologic effect of empiric systemic antibiotic therapy on the endogenous microflora was evaluated in 83 febrile granulocytopenic patients with cancer who were randomly allocated to receive moxalactam plus ticarcillin (45 patients) or tobramycin plus ticarcillin (38 patients) for suspected infection. Serial surveillance cultures of the nasal passages, oropharynx and feces performed twice a week showed that patients who received the former regimen had higher elimination rates and significantly lower acquisition rates (p = 0.027) for aerobic gram-negative bacilli than did patients who received the latter regimen. However, therapy with moxalactam plus ticarcillin also resulted in significantly higher acquisition rates for yeasts (p = 0.004). This was associated with a significantly higher fungal superinfection rate among these patients than among those who received tobramycin plus ticarcillin (40% v. 16%) (p less than 0.05). Moxalactam plus ticarcillin therapy created a greater microbial ecologic vacuum by the elimination of intestinal anaerobes, which, in turn, permitted fungal colonization and an increased risk of superinfection. Our results support the recommendation that an antipseudomonal penicillin plus an aminoglycoside be selected as empiric therapy for suspected infection in febrile granulocytopenic patients with cancer. Such a regimen would spare the anaerobic intestinal microflora, thereby reducing the risk of fungal colonization and infection.
Similar articles
-
A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.Am J Med. 1986 May 30;80(5C):101-11. Am J Med. 1986. PMID: 3521269 Clinical Trial.
-
Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients.Arch Intern Med. 1984 Sep;144(9):1766-70. Arch Intern Med. 1984. PMID: 6383246
-
A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients.Arch Intern Med. 1985 Jun;145(6):1083-8. Arch Intern Med. 1985. PMID: 3890789 Clinical Trial.
-
Preservation of colonization resistance parameters during empiric therapy with aztreonam in the febrile neutropenic patient.Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S747-61. doi: 10.1093/clinids/7.supplement_4.s747. Rev Infect Dis. 1985. PMID: 3909333 Review.
-
Monotherapy for empiric treatment of fever in granulocytopenic cancer patients.Am J Med. 1986 May 30;80(5C):85-95. Am J Med. 1986. PMID: 3521273 Review.
Cited by
-
Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment.PLoS One. 2013 Aug 19;8(8):e71806. doi: 10.1371/journal.pone.0071806. eCollection 2013. PLoS One. 2013. PMID: 23977147 Free PMC article.
-
Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis.Microbiome. 2014 Nov 3;2:40. doi: 10.1186/2049-2618-2-40. eCollection 2014. Microbiome. 2014. PMID: 25408892 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical